ArticleNature communications2020
Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Blood-based multiplex nanobiosensing of Alzheimer's disease biomarkers: from nanoengineered ınterfaces to clinical translation.Metabolic brain disease · 2026Review
- Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer's disease.Biological research · 2026Review
- Interface Quality Control of Self-Assembled Monolayer for Highly Sensitive Protein Detection Based on EGOFETs.Sensors (Basel, Switzerland) · 2026Article
- New SPRi Biosensors for Simultaneous Detection of Tau Protein Isoforms-The Importance of the Ptau181/Total Tau Ratio in Alzheimer's Disease.Biomedicines · 2026Article
- Utilizing nanotechnology to diagnose and treat central nervous system disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Photonic Nanomaterials for Wearable Health Solutions.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Material-based neuroimaging and biomarker detection for central nervous system disorder.Materials today. Bio · 2025Review
- Expert Guidance on Cognitive Impairment in Alzheimer's Disease: A Practical Seven-Step Approach from the United Arab Emirates.Neurology and therapy · 2025Article
- Article
- Carbon Nanomaterial-Based Electrochemical Biosensors for Alzheimer's Disease Biomarkers: Progress, Challenges, and Future Perspectives.Biosensors · 2025Review
- A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?Analytical and bioanalytical chemistry · 2025Review
- Functional discrimination of CSF from Alzheimer's patients in a brain on chip platform.Scientific reports · 2025Article
- Carbon nanomaterials as smart interfaces in ultrathin films for high-performance electrochemical sensors: a critical review.RSC advances · 2025Review
- Polyethylene Glycol Nanofiller for Robust Lyophilization of Graphically Encoded Hydrogel Microparticles.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Rigid DNA Frameworks Anchored Transistor Enabled Ultrasensitive Detection of Aβ-42 in Serum.Sensors (Basel, Switzerland) · 2025Article
- tRFAlzheimer's research & therapy · 2025Article
- Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.Biosensors · 2025Review
- Biological determinants of blood-based biomarker levels in Alzheimer's disease: role of nutrition, inflammation, and metabolic factors.Frontiers in aging neuroscience · 2025Review
- Recent advances in bio-integrated electrochemical sensors for neuroengineering.Fundamental research · 2025Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, affecting one in ten people aged over 65 years. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Here we report clinically accurate and ultrasensitive detection of multiple AD core biomarkers (t-tau, p-tau
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.